These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21118388)

  • 21. [Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area].
    Tanaka N; Manabe M; Yamashita S; Ikeda K; Obayashi K; Uchiba M; Ando Y
    Rinsho Byori; 2013 Jul; 61(7):576-82. PubMed ID: 24205697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
    Francis JL; Hursting MJ
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.
    Okuda M; Yamamoto Y
    Clin Lab Haematol; 2004 Jun; 26(3):215-23. PubMed ID: 15163321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor.
    Despotis GJ; Hogue CW; Santoro SA; Joist JH; Barnes PW; Lappas DG
    Crit Care Med; 1995 Oct; 23(10):1674-9. PubMed ID: 7587232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlation between plasma concentration of heparin and biological response determined by 2 APTT reagents of different sensitivities].
    Bassini E; Miceli M; Cini S; Francalanci R
    Quad Sclavo Diagn; 1986 Jun; 22(2):193-200. PubMed ID: 3823368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The APTT monitoring of heparin--the ISTH/ICSH collaborative study.
    Van der Velde EA; Poller L
    Thromb Haemost; 1995 Jan; 73(1):73-81. PubMed ID: 7740500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activated partial thromboplastin time as a monitor of heparin therapy: a warning.
    Makary AZ; Waterbury L
    Johns Hopkins Med J; 1977 Jun; 140(6):311-5. PubMed ID: 864903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies of phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin.
    Barrowcliffe TW; Gray E
    Thromb Haemost; 1981 Oct; 46(3):634-7. PubMed ID: 7314057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated partial thromboplastin time reagents: an evaluation.
    Howarth S
    Br J Biomed Sci; 1993 Jun; 50(2):109-13. PubMed ID: 8219915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A proposed model to monitor heparin therapy using the concentrated thrombin time which allows standardisation of reagents and improved estimation of heparin concentrations.
    Ray MJ; Perrin EJ; Smith IR; Hawson GA
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):515-21. PubMed ID: 8874861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.
    D'Angelo A; Seveso MP; D'Angelo SV; Gilardoni F; Dettori AG; Bonini P
    Am J Clin Pathol; 1990 Sep; 94(3):297-306. PubMed ID: 2396604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.